Literature DB >> 19549522

c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice.

Yuzo Kodama1, Tatiana Kisseleva, Keiko Iwaisako, Kouichi Miura, Kojiro Taura, Samuele De Minicis, Christoph H Osterreicher, Bernd Schnabl, Ekihiro Seki, David A Brenner.   

Abstract

BACKGROUND & AIMS: c-Jun N-terminal kinase (JNK) plays a pivotal role in the development of the metabolic syndrome including nonalcoholic fatty liver disease. However, the mechanism underlying the contribution of JNK to the progression from simple steatosis to steatohepatitis and liver fibrosis is unresolved.
METHODS: Hepatic steatosis, inflammation, and fibrosis were examined in wild-type, jnk1(-/-), or jnk2(-/-) mice fed a choline-deficient L-amino acid-defined (CDAA) diet for 20 weeks. The functional contribution of JNK isoforms in Kupffer cells was assessed in vitro and in vivo using chimeric mice in which the hematopoietic compartment including Kupffer cells was replaced by wild-type, jnk1(-/-), or jnk2(-/-) cells.
RESULTS: CDAA diet induced significantly less hepatic inflammation and less liver fibrosis despite a similar level of hepatic steatosis in jnk1(-/-) mice as compared with wild-type or jnk2(-/-) mice. CDAA diet-induced hepatic inflammation was chronic and mediated by Kupffer cells. Pharmacologic inhibition of JNK or gene deletion of jnk1 but not jnk2 repressed the expression of inflammatory and fibrogenic mediators in primary Kupffer cells. In vivo, CDAA diet induced less hepatic inflammation and liver fibrosis despite an equivalent level of hepatic steatosis in chimeric mice with jnk1(-/-) hematopoietic cells as compared with chimeric mice with wild-type or jnk2(-/-) hematopoietic cells.
CONCLUSIONS: jnk1(-/-) mice are resistant to diet-induced steatohepatitis and liver fibrosis. JNK1 in hematopoietic cells, especially in Kupffer cells, contributes to the development of liver fibrosis by inducing chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549522      PMCID: PMC2757473          DOI: 10.1053/j.gastro.2009.06.045

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  45 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

Review 2.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

3.  CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.

Authors:  I A Leclercq; G C Farrell; J Field; D R Bell; F J Gonzalez; G R Robertson
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

4.  c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration.

Authors:  Robert F Schwabe; Cynthia A Bradham; Tetsuya Uehara; Etsuro Hatano; Brydon L Bennett; Robert Schoonhoven; David A Brenner
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

5.  Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis.

Authors:  Naga Chalasani; J Christopher Gorski; Maleeha S Asghar; Ali Asghar; Brian Foresman; Stephen D Hall; David W Crabb
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

Review 6.  Molecular mediators of hepatic steatosis and liver injury.

Authors:  Jeffrey D Browning; Jay D Horton
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

7.  A central role for JNK in obesity and insulin resistance.

Authors:  Jiro Hirosumi; Gürol Tuncman; Lufen Chang; Cem Z Görgün; K Teoman Uysal; Kazuhisa Maeda; Michael Karin; Gökhan S Hotamisligil
Journal:  Nature       Date:  2002-11-21       Impact factor: 49.962

8.  Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice.

Authors:  Emilia Ip; Geoff Farrell; Pauline Hall; Graham Robertson; Isabelle Leclercq
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

9.  Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis.

Authors:  Yuzo Kodama; Kojiro Taura; Kouichi Miura; Bernd Schnabl; Yosuke Osawa; David A Brenner
Journal:  Gastroenterology       Date:  2009-01-06       Impact factor: 22.682

10.  Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.

Authors:  Varman T Samuel; Zhen-Xiang Liu; Xianqin Qu; Benjamin D Elder; Stefan Bilz; Douglas Befroy; Anthony J Romanelli; Gerald I Shulman
Journal:  J Biol Chem       Date:  2004-05-27       Impact factor: 5.157

View more
  81 in total

1.  Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice.

Authors:  Kouichi Miura; Yuzo Kodama; Sayaka Inokuchi; Bernd Schnabl; Tomonori Aoyama; Hirohide Ohnishi; Jerrold M Olefsky; David A Brenner; Ekihiro Seki
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

2.  Distinct functions of JNK and c-Jun in oxidant-induced hepatocyte death.

Authors:  Muhammad Amir; Kun Liu; Enpeng Zhao; Mark J Czaja
Journal:  J Cell Biochem       Date:  2012-10       Impact factor: 4.429

3.  TNFα in liver fibrosis.

Authors:  Yoon Mee Yang; Ekihiro Seki
Journal:  Curr Pathobiol Rep       Date:  2015-09-30

Review 4.  Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame.

Authors:  Samar H Ibrahim; Petra Hirsova; Harmeet Malhi; Gregory J Gores
Journal:  Dig Dis Sci       Date:  2015-12-01       Impact factor: 3.199

5.  Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha.

Authors:  Bo Wang; Shu-Hao Hsu; Wendy Frankel; Kalpana Ghoshal; Samson T Jacob
Journal:  Hepatology       Date:  2012-06-05       Impact factor: 17.425

6.  Expression of STING Is Increased in Liver Tissues From Patients With NAFLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice.

Authors:  Xianjun Luo; Honggui Li; Linqiang Ma; Jing Zhou; Xin Guo; Shih-Lung Woo; Ya Pei; Linda R Knight; Michael Deveau; Yanming Chen; Xiaoxian Qian; Xiaoqiu Xiao; Qifu Li; Xiangbai Chen; Yuqing Huo; Kelly McDaniel; Heather Francis; Shannon Glaser; Fanyin Meng; Gianfranco Alpini; Chaodong Wu
Journal:  Gastroenterology       Date:  2018-09-10       Impact factor: 22.682

7.  Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.

Authors:  Margarita Pizarro; Nancy Solís; Pablo Quintero; Francisco Barrera; Daniel Cabrera; Pamela Rojas-de Santiago; Juan P Arab; Oslando Padilla; Juan C Roa; Han Moshage; Alexander Wree; Eugenia Inzaugarat; Ariel E Feldstein; Carlos E Fardella; Rene Baudrand; Arnoldo Riquelme; Marco Arrese
Journal:  Liver Int       Date:  2015-02-23       Impact factor: 5.828

8.  Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis.

Authors:  Sayaka Inokuchi; Tomonori Aoyama; Kouichi Miura; Christoph H Osterreicher; Yuzo Kodama; Katsumi Miyai; Shizuo Akira; David A Brenner; Ekihiro Seki
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-18       Impact factor: 11.205

Review 9.  Regulation of glucose metabolism in hepatocarcinogenesis by microRNAs.

Authors:  Ryan K Reyes; Tasneem Motiwala; Samson T Jacob
Journal:  Gene Expr       Date:  2014

10.  Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition.

Authors:  Johannes Kluwe; Jean-Philippe Pradere; Geum-Youn Gwak; Ali Mencin; Samuele De Minicis; Christoph H Osterreicher; Jordi Colmenero; Ramon Bataller; Robert F Schwabe
Journal:  Gastroenterology       Date:  2009-09-24       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.